Evidence map›Paper›PMID 41683741›Full record

ReviewInternational journal of molecular sciences2026

Breast Cancer Multicellular Spheroid Models-A Tool for Studying Cancer Biology; a Possible Platform for Drug Screening and Personalized Medicine.

Maksymilian Kolodziej, Jakub Czarny, Hanna Dyla, Dominika Rekawek, Maria Zlotek, Alicja Wlodarz, Michal Baranowicz, Eliza Kwiatkowska-Borowczyk, Olga Milbrandt, Rodryg Ramlau and 1 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maksymilian KolodziejStudent Scientific Society, Poznan University of Medical Sciences, 61-701 Poznan, Poland.ORCID 0000-0002-3889-1588
Jakub CzarnyStudent Scientific Society, Poznan University of Medical Sciences, 61-701 Poznan, Poland.ORCID 0000-0003-4996-9157
Hanna DylaFaculty of Medicine, Collegium Medicum, The University of Opole, 45-040 Opole, Poland.
Dominika RekawekFaculty of Medicine, Collegium Medicum, The University of Opole, 45-040 Opole, Poland.
Maria ZlotekFaculty of Medicine, Collegium Medicum, The University of Opole, 45-040 Opole, Poland.
Alicja WlodarzFaculty of Medicine, Collegium Medicum, The University of Opole, 45-040 Opole, Poland.
Michal BaranowiczStudent Scientific Society, Poznan University of Medical Sciences, 61-701 Poznan, Poland.ORCID 0009-0008-6789-5917
Eliza Kwiatkowska-BorowczykDepartment of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland.ORCID 0000-0003-1620-7965
Olga MilbrandtOncology Clinic, Institute of Oncology, Poznan University of Medical Sciences, 61-701 Poznan, Poland.ORCID 0000-0002-7553-7676
Rodryg RamlauOncology Clinic, Institute of Oncology, Poznan University of Medical Sciences, 61-701 Poznan, Poland.ORCID 0000-0002-3199-2298
Hanna Dams-KozlowskaDepartment of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland.ORCID 0000-0003-2349-419X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a growing pressure for further breast cancer treatment development to improve patient quality of life and clinical effectiveness while reducing drug resistance and side effects. Clinical research, however, remains both expensive and time-consuming, highlighting the importance of advancing preclinical studies. The ability of a model to accurately replicate the biological environment is essential for generating reliable data. Although research on two-dimensional in vitro cell culture systems has been conducted for over a century, their limited complexity hinders further development of cancer treatments. Consequently, the response to tested medications is artificial, since some drugs appear to be effective only in the two-dimensional model and not in clinical settings. A multicellular spheroid (MCS) is a three-dimensional assembly of cancer cells, used in oncology to study cancer biology and drug sensitivity. MCSs serve as valuable in vitro models in preclinical drug development. They can also be used in a clinical setting as a personalized tool for drug susceptibility screening. The objective of this review is to highlight new possibilities for improved anticancer drug screening and the development of personalized treatment regimens with multicellular spheroids.

Indexed as

Antineoplastic AgentsBreast NeoplasmsPrecision MedicineSpheroids, CellularAnimalsDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorFemaleHumansModels, BiologicalAntineoplastic Agentsbreast cancermulticellular spheroidspersonalized medicinepreclinical drug development

Identifiers

PMID41683741
PMCPMC12898193

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.